KLK3 and neoplasm: Under the assumptions that the risk of developing CRPC can be measured by analyzing the PSA response to hormone therapy and that castration resistance is heterogeneous among the individual tumor cells within a patient, we investigated the value of the PSAT1⁄2 during neoadjuvant ADT as a predictive factor for CRPC in radical prostatectomy patients who developed BCR.